Lifestyle

Maunzao Purchased Abroad: Repeated Imports Will Be Blocked at Customs

Ministry of Food and Drug Safety Determines Repeated Imports by Checking Immigration Records and Overseas Payment History Prescription Prices at Some Japanese Hospitals Are One-Fifth of Those in Korea… Concerns Over the Spread of Cross-Border Purchases

NA EUN-KYUNG
2026-11-18 17:34:02
[Edaily Reporter NA EUN-KYUNG ] While it is now permitted to bring the obesity treatments “Mounjaro” and “Wegovy”—prescribed overseas—into South Korea, repeated imports may result in customs clearance being suspended. The government’s policy is to allow the import of medications for personal treatment while preventing bulk purchases and domestic resale that exploit this allowance.

According to the pharmaceutical and biotech industry on the 18th, the Ministry of Food and Drug Safety (MFDS) recently stated in response to inquiries from a group of journalists specializing in immigration and customs that it will not permit the repeated importation of medications for purposes other than personal treatment. The Korea Customs Service plans to determine the purpose of importation by comprehensively reviewing factors such as the traveler’s frequency of entry and exit, past inspection records, and overseas payment history.

The Ministry of Food and Drug Safety and the Korea Customs Service began allowing travelers to bring in medications for self-treatment—formally prescribed and purchased overseas—as personal carry-on items starting on the 12th. In principle, travelers may bring in up to six bottles; even if this limit is exceeded, the amount is permitted as long as it does not exceed a three-month supply based on the medication’s recommended dosage. For obesity treatments administered via weekly injection, this corresponds to a maximum of 12 doses.

Eli Lilly’s GLP-1 obesity treatment “Mounjaro” (Photo: Eli Lilly)


This measure was implemented to reduce inconvenience for patients receiving treatment abroad or those who left the country with medications prescribed domestically and are now re-entering. Previously, there were cases where even medications obtained through proper prescriptions were restricted at customs during the import process. This change comes in response to concerns that a distinction must be made between the direct purchase of overseas medications and their import for personal medical use.

Since the policy change, the most closely watched category has been glucagon-like peptide (GLP)-1 obesity treatments. In South Korea, Novo Nordisk’s Wegovy was launched in October 2024, and Eli Lilly’s Mounjaro was launched last August. Last month, treatment options expanded further when HanmiPharm(128940)launched “Epe,” the first domestically developed GLP-1 obesity treatment.

The growing interest in cross-border prescriptions for obesity treatments stems from price differences between countries. The domestic supply price for a four-week supply of Mounjaro at its lowest dosage of 2.5 mg is approximately 280,000 won, while the actual price patients pay typically exceeds 300,000 won. In contrast, it is reported that some medical institutions in Japan prescribe a four-week supply of the same dosage for approximately 7,000 yen (59,000 won). This means the out-of-pocket cost for patients in South Korea is more than five times higher than the price at some Japanese hospitals.

As word spread that Mounjaro is cheaper in Japan, interest has also grown in the so-called “Sushi-Jaro”—the practice of bringing medication prescribed in Japan back to Korea. According to the Korea Customs Service, from January to August of this year, there were 1,097 cases of illegal importation of Wegovy and Mounjaro via travelers’ personal belongings—more than eight times the 134 cases recorded for the entire previous year.

In response, the Ministry of Food and Drug Safety (MFDS) has stated that even if the permitted import quantity is met, it will investigate whether repeated purchases and imports align with the purpose of self-treatment. Selling imported medications to others or providing them free of charge may also constitute a violation of the Pharmaceutical Affairs Act.

The MFDS plans to monitor the illegal distribution of medicines imported from overseas—primarily online—and, if violations are confirmed, take enforcement action through special judicial police officers. Illegal sales or distribution may be punishable by up to five years in prison or a fine of up to 50 million won, in accordance with relevant laws and regulations.

Concerns have also been raised regarding the safety management of medicines imported from overseas. In particular, injectable obesity treatments such as Wegovy and Mounjaro require strict adherence to product-specific storage conditions, making proper handling during the process of transporting them from overseas into the country critical.

Unlike medicines officially distributed in Korea, products purchased directly overseas by individuals and brought into the country are not covered by the Pharmaceutical Affairs Act’s compensation system for adverse drug reactions. This means that even if adverse effects occur, it is difficult to receive compensation through the domestic compensation system.

The Korean Society of Endocrinology, the Korean Diabetes Association, and the Korean Society for the Study of Obesity also issued a joint statement on the same day, urging the establishment of a regulatory framework for the importation of overseas medications. The three societies emphasized the need to establish effective procedures to verify prescriptions and purchases, as well as to specify criteria for determining whether repeated imports are permitted and what quantities are allowed.

The medical community also called for institutional reforms to reduce the demand for overseas purchases driven by price differences. The three societies pointed out that the financial burden of non-covered medical expenses in Korea is one of the factors behind “prescription tourism” and requested that the National Health Insurance Service (NHIS) swiftly finalize the process for covering Maunzaro as a treatment for type 2 diabetes.

The Ministry of Food and Drug Safety (MFDS) stated, “While we will allow the personal import of medications for individual treatment, we will block illegal distribution and strengthen oversight to ensure safe use,” adding, “In particular, when purchasing medications overseas, it is necessary to follow proper prescription procedures and thoroughly verify storage conditions.”

Economy

Corporation

IT·Science

Economy

HyundaiMotor Group Completes Restructuring Focused on Commercial Robots… Atlas Welcomes Its First Semiconductor Customer

Boston Dynamics’ humanoid robot Atlas (right) and quadruped robot Spot (left). (Photo courtesy of HyundaiMotor Group) HyundaiMotor Group has completed a business restructuring centered on commerci…
2026-11-18 17:17:41

Corporation

Maunzao Purchased Abroad: Repeated Imports Will Be Blocked at Customs

While it is now permitted to bring the obesity treatments “Mounjaro” and “Wegovy”—prescribed overseas—into South Korea, repeated imports may result in customs clearance being suspended. The government…
2026-11-18 17:34:02

IT·Science

PearlAbyss Corp.’s ‘Red Desert’ Wins 8 Daesangs at the Game Awards… Makes History

PearlAbyss Corp.(263750) “Red Desert” made history for the Korean gaming industry by winning eight awards, including the Daesang, at the “2026 Korea Game Awards,” which selects the nation’s best game …
2026-11-18 17:40:13